Peri-procedural Elevated Myocardial Biomarkers Predict Adverse Clinical Outcomes Following Elective Percutaneous Coronary Intervention: A Comprehensive Dose-Response Meta-Analysis of 24 Prospective Studies with 44972 patients.
The optimal cut-off value of isolated cardiac biomarker elevation for defining prognostically important percutaneous coronary intervention (PCI)-related myocardial injury is not known. We performed a meta-analysis to evaluate the dose-response relationship between isolated cardiac biomarker elevations and risk of all-cause mortality following elective PCI. 24 prospective studies (44972 patients) were included. Patients with an isolated elevation of cardiac biomarkers, had increased risk of all-cause mortality when compared to those with no elevations (cardiac troponin I: odds ratio (OR) 1.42, 95% confidence interval (CI) 1.19-1.69; creatine kinase-MB isoenzyme (CK-MB) OR 1.43, 95% CI 1.19-1.70). For the dose-response analysis, elevations of cardiac troponin I &gt;3x or CK-MB&gt;1x99th percentile upper reference limit (URL) were associated with increased mortality (cardiac troponin I: OR 1.51 95% CI 1.05-2.17; CK-MB: OR 1.25, 95% CI 1.05-1.48). The pooled OR of mortality for each 3xURL increment of cardiac troponin I or CK-MB were 1.33 (95% CI 1.15-1.53) and 1.38 (95% CI 1.30 -1.47). We found a positive dose-response relationship between isolated cardiac troponin I and CK-MB with all-cause mortality and elevated cardiac troponin I &gt; 3x or CK-MB &gt; 1x the 99th percentile URL was associated with the increased risk of mortality.